In:
Future Oncology, Future Medicine Ltd, Vol. 18, No. 38 ( 2022-12), p. 4153-4160
Kurzfassung:
Plain language summary An ongoing study to evaluate encorafenib, binimetinib and cetuximab for people with early recurrent BRAF V600E-mutated colorectal cancer. BRAF V600E-mutated colorectal cancer (CRC) is a type of cancer caused by change (mutation) in a gene called BRAF. It is one of the most difficult types of CRC to treat because currently available drugs do not effectively treat the disease. Recently, two novel treatments, encorafenib and cetuximab, have been approved for use together in several countries for the treatment of advanced or metastatic BRAF V600E-mutated CRC. In Japan, these drugs are also approved to be given with another treatment called binimetinib, an approach called triplet therapy. This article describes the ongoing TRESBIEN study that is looking at how effective and how safe triplet therapy is for the treatment of people with early recurrent BRAF V600E-mutated CRC, during or after they have additional (adjuvant) chemotherapy. This study is ongoing, and the researchers are currently recruiting new participants. TRESBIEN will evaluate the percentage of participants whose tumors shrink with triplet therapy. The study will also look at any side effects. Clinical Trial Registration: jRCTs051210152 ( ClinicalTrials.gov ) (Japan Registry of Clinical Trials https://jrct.niph.go.jp/search?language=en & page=1).
Materialart:
Online-Ressource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2022-0949
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2022